

# Bacillary Dysentery - Pipeline Review, H2 2019

<https://marketpublishers.com/r/BD1426AE8D0FEN.html>

Date: November 2019

Pages: 55

Price: US\$ 2,000.00 (Single User License)

ID: BD1426AE8D0FEN

## Abstracts

Bacillary Dysentery - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2019, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape.

Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps and fever. Predisposing factors include eating contaminated food, age, international travelers and homosexual men. Treatment includes antibiotics.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 5 and 2 respectively.

Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 2 molecules, respectively.

Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route

of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Bacillary Dysentery (Shigellosis) - Overview

Bacillary Dysentery (Shigellosis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacillary Dysentery (Shigellosis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development

Akthelia Pharmaceuticals Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Immuron Ltd

LimmaTech Biologics AG

Protein Potential LLC

Bacillary Dysentery (Shigellosis) - Drug Profiles

(shigella + typhoid) (Bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKT-10081 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3536852A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3902986A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress  
IMM-124E - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
infectious disease vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
SC-599 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
SF2a-TT15 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
shigella (bivalent) vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
shigella [serotype 2a] vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
shigella [strain 53G] vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
shigella vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
shigella vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
shigella vaccine - Drug Profile  
Product Description

Mechanism Of Action

R&D Progress

shigella vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Shigetec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacillary Dysentery (Shigellosis) - Dormant Projects

Bacillary Dysentery (Shigellosis) - Product Development Milestones

Featured News & Press Releases

Oct 07, 2019: EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella

Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine

Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions

Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease

Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine

Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Bacillary Dysentery (Shigellosis) - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2019

Bacillary Dysentery (Shigellosis) - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2019

Bacillary Dysentery (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H2 2019

Bacillary Dysentery (Shigellosis) - Pipeline by Immuron Ltd, H2 2019

Bacillary Dysentery (Shigellosis) - Pipeline by LimmaTech Biologics AG, H2 2019

Bacillary Dysentery (Shigellosis) - Pipeline by Protein Potential LLC, H2 2019

Bacillary Dysentery (Shigellosis) - Dormant Projects, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Akthelia Pharmaceuticals Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Immuron Ltd

LimmaTech Biologics AG

Protein Potential LLC



## I would like to order

Product name: Bacillary Dysentery - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/BD1426AE8D0FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD1426AE8D0FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970